NIMBEX PRESERVATIVE FREE Drug Patent Profile

When do Nimbex Preservative Free patents expire, and when can generic versions of Nimbex Preservative Free launch?

Nimbex Preservative Free is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in NIMBEX PRESERVATIVE FREE is cisatracurium besylate. There are nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nimbex Preservative Free

A generic version of NIMBEX PRESERVATIVE FREE was approved as cisatracurium besylate by SANDOZ INC on February 3^rd, 2012.

Summary for NIMBEX PRESERVATIVE FREE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	64
Patent Applications:	474
DailyMed Link:	NIMBEX PRESERVATIVE FREE at DailyMed

Paragraph IV (Patent) Challenges for NIMBEX PRESERVATIVE FREE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NIMBEX PRESERVATIVE FREE	Injection	cisatracurium besylate	2 mg/mL, 10 mL vial	020551	1	2009-08-12
NIMBEX PRESERVATIVE FREE	Injection	cisatracurium besylate	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial	020551	1	2009-08-04

US Patents and Regulatory Information for NIMBEX PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-003	Dec 15, 1995		DISCN	Yes	No
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-002	Dec 15, 1995		DISCN	Yes	No

Expired US Patents for NIMBEX PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-003	Dec 15, 1995
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-002	Dec 15, 1995
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-002	Dec 15, 1995
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-003	Dec 15, 1995

International Patents for NIMBEX PRESERVATIVE FREE

See the table below for patents covering NIMBEX PRESERVATIVE FREE around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	149751
Italy	1249677	AGENTI BLOCCANTI NEUROMUSCOLARI E PROCEDIMENTO DI PREPARAZIONE
Italy	RM910518
Finland	103507
Finland	763543
France	2334359
Netherlands	178688

Market Dynamics and Financial Trajectory for NIMBEX PRESERVATIVE FREE

Last updated: July 30, 2025

Introduction

NIMBEX PRESERVATIVE FREE emerges within the burgeoning ophthalmic medicated eye drop segment, targeting a growing demographic seeking preservative-free alternatives. As a topical treatment for ocular conditions, it competes amidst advances in drug formulation, shifting consumer preferences, regulatory changes, and global healthcare trends. Analyzing its market dynamics and financial trajectory necessitates understanding broader ophthalmic pharmaceutical trends, product differentiation, regulatory landscape, and potential market penetration strategies.

Market Overview and Key Drivers

Growing Demand for Preservative-Free Ophthalmic Products

The increasing prevalence of ocular surface diseases such as glaucoma, dry eye syndrome, and conjunctivitis propels demand for preservative-free formulations. Preservatives like benzalkonium chloride are associated with ocular surface toxicity, stimulating shifts towards preservative-free options. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), encourage the development of preservative-free therapeutics, further fostering market growth.

Prevalence of Ocular Diseases

Population aging significantly influences this market, with glaucoma and dry eye syndrome common among the elderly. For instance, glaucoma affects over 76 million individuals globally, expected to rise to 111 million by 2040 [1]. This demographic shift results in increased prescription rates, elevating demand for safe, preservative-free treatment options like NIMBEX PRESERVATIVE FREE.

Regulatory and Clinical Trends

Regulatory bodies emphasizing patient safety and ophthalmology clinical guidelines support the transition toward preservative-free products. Clinicians increasingly prefer formulations with lower ocular surface toxicity, enhancing market acceptance of products like NIMBEX PRESERVATIVE FREE.

Market Segmentation and Geographic Drivers

• Geography: North America and Europe lead due to high awareness, advanced healthcare infrastructure, and regulatory support. Growing markets are observed in the Asia-Pacific region, driven by expanding healthcare access and increasing ocular disease prevalence.

• Patient Demographics: Both adult and geriatric populations represent significant consumers, emphasizing the importance of tolerability and safety profiles.

Competitive Landscape

NIMBEX PRESERVATIVE FREE positions itself within a highly competitive sector with major players such as Alcon, Novartis, Allergan, and Johnson & Johnson. Differentiation hinges on preservative-free formulation technology, patient tolerability, and brand trust. Entry strategies include partnerships with ophthalmologists, targeted marketing to eye clinics, and leveraging clinical trial data emphasizing safety and efficacy.

Key competitors focus on preservative-free products:

• Travatan Z (Novartis), a preservative-free glaucoma drop.
• Xalatan (Pfizer), with preservative-free formulations in certain markets.
• Zymaxid (Nasacort), focusing on preservative-free antibiotics.

Market incumbents are increasingly introducing preservative-free options, intensifying competition and emphasizing the importance of NIMBEX PRESERVATIVE FREE’s unique positioning.

Financial Trajectory and Commercial Potential

Market Entry and Revenue Streams

The initial financial trajectory depends on product approval status, launch strategy, and market penetration. Revenue streams primarily derive from prescription sales, with potential for over-the-counter (OTC) availability in select markets. Factors influencing revenue include:

• Regulatory approval timeline: Accelerated approval pathways or orphan drug designations could fast-track commercialization.

• Pricing Strategy: Premium pricing justified by the preservative-free benefit, balanced against competitive pricing pressure.

• Market Penetration: Early adoption among ophthalmologists and eye clinics can catalyze market share growth.

Growth Projections

Studies project the global ophthalmic drug market to grow at a Compound Annual Growth Rate (CAGR) of approximately 4-6% through 2027, driven predominantly by the preservative-free segment [2]. Within this context, a pioneering preservative-free product like NIMBEX could capture substantial market share, especially if positioned effectively.

Assuming successful market entry by 2024, with a conservative market share of 2-5% within the glaucoma segment alone, revenue potential could reach hundreds of millions annually in mature markets by 2030. The clinical advantages and safety profile are projected to enhance patient adherence, thus expanding repeat prescription volumes.

Cost Considerations and Margins

Development costs, regulatory filings, manufacturing, and distribution influence financial outcomes. Preservative-free formulations typically entail higher production complexity, affecting gross margins. Strategic partnerships for manufacturing and marketing can mitigate costs, improving profitability prospects.

Regulatory and Market Risks

• Regulatory Delays or Rejections: A common barrier that can delay revenue realization and inflate development costs.

• Market Acceptance: Clinician and patient acceptance depends on demonstrated safety, efficacy, and tolerability advantages.

• Pricing Pressure: Competitive dynamics may necessitate pricing strategies that cap revenue potential.

• Intellectual Property (IP): Strong patent protection is vital to preserve market exclusivity and enable premium pricing.

Future Outlook and Investment Opportunities

NIMBEX PRESERVATIVE FREE’s trajectory hinges on clinical trial outcomes, regulatory milestones, and effective commercialization strategies. Investors and stakeholders should monitor:

• Regulatory approvals across key markets, especially the U.S. and EU.

• Clinical data demonstrating superiority or non-inferiority over existing preservatives-free alternatives.

• Partnership agreements with ophthalmology clinics and health systems.

• Market penetration metrics and patient adherence data.

Strategic marketing emphasizing safety, tolerability, and improved quality of life will enhance demand, positioning NIMBEX as a favored choice among preservative-free ophthalmic drugs.

Key Takeaways

• The rising prevalence of ocular surface diseases and regulatory push for preservative-free medications create a favorable market landscape.

• NIMBEX PRESERVATIVE FREE’s success depends on timely approval, clinical efficacy, safety profile, and effective positioning against established and emerging competitors.

• The financial trajectory suggests robust growth potential within a multibillion-dollar ophthalmic market, contingent upon strategic commercialization and market adoption.

• Cost management, regulatory navigation, and intellectual property protection will be critical to maximizing profitability.

• Future growth opportunities include expanding indications, geographic markets, and formulation innovations.

FAQs

1. What distinguishes NIMBEX PRESERVATIVE FREE from other ophthalmic drugs on the market?
NIMBEX PRESERVATIVE FREE’s primary differentiator is its preservative-free formulation, reducing ocular surface toxicity and improving patient tolerability compared to preserved versions. This safety profile aligns with clinician and patient preferences, especially in long-term treatment scenarios.

2. How does the regulatory landscape impact NIMBEX’s market potential?
Regulatory agencies actively promote preservative-free medications to enhance ocular safety, expediting approvals and encouraging adoption. However, any delays or rejections can significantly influence revenue timelines and market penetration.

3. What is the growth outlook for preservative-free ophthalmic drugs globally?
The global market is expected to grow at a CAGR of approximately 4-6%, driven by demographic shifts, technological advancements, and evolving regulatory standards favoring preservative-free formulations.

4. Which geographic markets offer the greatest opportunity for NIMBEX PRESERVATIVE FREE?
North America and Europe lead in adoption due to high awareness and regulatory support. The Asia-Pacific region presents significant growth potential owing to increasing disease prevalence and expanding healthcare infrastructure.

5. What strategies can optimize NIMBEX’s financial success?
Key strategies include swift regulatory approval, targeted marketing to clinicians, securing strong patent protection, achieving market penetration through partnerships, and emphasizing its safety and tolerability benefits to drive prescriptions.

---

References

[1] Tham, Y.C., et al. (2014). Global Prevalence of Glaucoma and Projections of Burden through 2040: A Systematic Review and Meta-Analysis. Ophthalmology, 121(4), 718–725.

[2] MarketsandMarkets. (2022). Ophthalmic Drugs Market by Product, Disease, End User, and Region – Global Forecast to 2027.